Table 1.
Patient demographics and genomic characteristics.
| Baseline characteristic (N = 18) | N (%) |
|---|---|
| Age at initiation of matched therapy (median), years | 67 (47–84) |
| Sex | |
| Male, N (%) | 7 (38.9%) |
| Female, N (%) | 11 (61.1%) |
| Race | |
| White, N (%) | 15 (83.3%) |
| Hispanic, N (%) | 1 (5.6%) |
| Asian, N (%) | 1 (5.6%) |
| Black, N (%) | 1 (5.6%) |
| Extent of disease at diagnosis | |
| Localized, N (%) | 6 (33.3%) |
| Locally advanced, N (%) | 2 (11.1%) |
| Metastatic, N (%) | 10 (55.6%) |
| Extent of disease at time of matched therapy | |
| Locally advanced, N (%) | 2 (11.1%) |
| Metastatic, N (%) | 16 (88.9%) |
| Number of prior therapies, median (range) | 1.5 (0–4) |
| Matched therapy given as first-line therapy, N (%) | 5 (27.8%) |
| Matched therapy given as second line or greater, N (%) | 13 (72.2%) |
| Number of matched targeted agents, median (range) | 2.5 (1–4) |
| Therapies given prior to matched treatment (N = 13), N (%) | |
| Gemcitabine/nab-paclitaxel | 9 (50%) |
| FOFLIRINOX | 6 (33.3%) |
| Clinical Trial | 3 (16.7%) |
| Capecitabine | 2 (11.1%) |
| FOLFOX | 1 (5.6%) |
| 5-FU/liposomal irinotecan | 2 (11.1%) |
| Gemcitabine/erlotinib | 1 (5.6%) |
| Gemcitabine | 1 (5.6%) |
| Genomic profiling | |
| Tissue NGS obtained, N (%) | 15 (83.3%) |
| Blood ctDNA obtained, N (%) | 14 (77.8%) |
| Both ctDNA and tissue NGS obtained, N (%) | 11 (61.1%) |
| Tissue NGS Platformsa (N = 15) | |
| Foundation Oneb | 14 (77.8%) |
| Tempusb | 1 (5.6%) |
| Institutional Assay (UCSD) | 1 (5.6%) |
| ctDNA Platforms (N = 14) | |
| Guardant360 | 13 (72.2%) |
| Tempus | 1 (5.6%) |
| Matching score, median (range) | 50% (14–100%) |
ctDNA circulating-tumor DNA, FOLFIRINOX 5-fluorouracil, oxaliplatin, irinotecan, leucovorin, FOLFOX 5-fluorouracil, oxaliplatin, leucovorin, NGS next-generation sequencing.
aTesting laboratories:
Caris Life Sciences, https://www.carismolecularintelligence.com/molecular-testing-services/; Foundation One and Foundation ACT, https://www.foundationmedicine.com/; Guardant360, http://www.guardant360.com/; Tempus, https://www.tempus.com/genomic-sequencing/.
bOne patient underwent both Foundation One and Tempus NGS.